United States December 2021 Pfizer Novel Covid Oral Antiviral Treatment — 图库照片

仅供社论使用

United States - december, 16, 2021: Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study — 图库社论摄影

1000 × 880JPG3.33 × 2.93" • 300 dpi标准许可

2000 × 1760JPG6.67 × 5.87" • 300 dpi标准许可

5000 × 4400JPG16.67 × 14.67" • 300 dpi标准许可

super

10000 × 8800JPG33.33 × 29.33" • 300 dpi标准许可

5000 × 4400JPG16.67 × 14.67" • 300 dpi扩展许可

United States - december, 16, 2021: Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study

— 照片作者 Giovanni_Cancemi

作者Giovanni_Cancemi
537939978
找到类似的图片

同一系列:

用手丸

United States - december, 16, 2021: Paxlovid, Pfizers Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89 in Interim Analysis of Phase 23 EPIC-HR Study

United States December 2021 Paxlovid Pfizers Novel Covid Oral Antiviral — 图库照片

男人的头丸

Italy - January, 03, 2022: Molnupiravir capsule antiviral drug pill for anti Coronavirus(COVID-19) developed by Merck and Co. 3D Rendering

Italy January 2022 Molnupiravir Capsule Antiviral Drug Pill Coronavirus Covid — 图库照片

丸的人

Taly - January, 03, 2022 Molnupiravir capsule antiviral drug pill for anti Coronavirus (COVID-19) developed by Merck and Co. 3D Rendering

Taly January 2022 Molnupiravir Capsule Antiviral Drug Pill Coronavirus Covid — 图库照片

男人的头丸

Italy - January, 03, 2022: Molnupiravir capsule antiviral drug pill for anti Coronavirus (COVID-19) developed by Merck and Co. 3D Rendering

用手丸

丸的人

透明玻璃瓶与红色药丸

白人与丸

United States - december, 16, 2021: Paxlovid, Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study

United States December 2021 Paxlovid Pfizer Novel Covid Oral Antiviral — 图库照片

United States - december, 16, 2021 Pfizers Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89 in Interim Analysis of Phase 23 EPIC-HR Study

United States December 2021 Pfizers Novel Covid Oral Antiviral Treatment — 图库照片

使用信息

根据标准许可，您可以将此免版税社论图片“ United States - december, 16, 2021: Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study ”用于个人和非商业目的。此库存图片可用于描绘报纸、杂志文章以及博客文章中的故事。请注意，社论库存图片不得用于广告或推广材料。

您可以购买这张社论图片，并以高达5000x4400 的高分辨率下载。上传日期: 2021年12月25日

United States - december, 16, 2021: Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study — 图库社论摄影

United States - december, 16, 2021: Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study

社论照片关键字:

同一系列:

使用信息